Combinatory therapy for cancer using biphenyl compound and immune checkpoint molecule regulator
AssigneesTaiho Pharmaceutical Co., Ltd., Astex Pharmaceuticals, Inc.
InventorsAkiko Osada, Toshihiro Shibutani
Life of this patent
Estimating the term…
Abstract
Provided is a novel cancer treatment method which exhibits a remarkably excellent antitumor effect with little side effects. An antitumor agent includes a biphenyl compound for use in a treatment of a subject having cancer. The treatment comprises administering an immune checkpoint molecule regulator to the subject.
Claims26
An antitumor agent comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for use in a treatment of a subject having cancer, wherein the treatment comprises administering an immune checkpoint molecule regulator to the subject.
An antitumor effect enhancing agent for an immune checkpoint molecule regulator, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof as an active ingredient.
An antitumor agent for treating a cancer patient given an immune checkpoint molecule regulator, the antitumor agent comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl] phenyl]-2-fluoro-benzonitrile or a salt thereof.
An antitumor agent for treating a cancer patient given 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof, the antitumor agent comprising an immune checkpoint molecule regulator.
4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for use in treating a tumor by administration thereof in combination with an immune checkpoint molecule regulator.
4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for use in enhancing the antitumor effect of an immune checkpoint molecule regulator.
4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for use in treating a tumor in a cancer patient given an immune checkpoint molecule regulator.
An immune checkpoint molecule regulator for use in treating a tumor in a cancer patient given 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl] phenyl]-2-fluoro-benzonitrile or a salt thereof.
A combination of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof and an immune checkpoint molecule regulator for use in treating a tumor.
Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl] phenyl]-2-fluoro-benzonitrile or a salt thereof for producing an antitumor agent which is administered in combination with an immune checkpoint molecule regulator.
Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl] phenyl]-2-fluoro-benzonitrile or a salt thereof for producing an antitumor effect enhancing agent for enhancing the antitumor effect of an immune checkpoint molecule regulator.
Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof for producing an antitumor agent for treating a cancer patient given an immune checkpoint molecule regulator.
Use of an immune checkpoint molecule regulator for producing an antitumor agent for treating a cancer patient given 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof.
Use of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof and an immune checkpoint molecule regulator for producing an antitumor agent.
A method for treating a tumor, comprising administering to a subject in need thereof 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof and an immune checkpoint molecule regulator in combination.
A method for enhancing the antitumor effect of an immune checkpoint molecule regulator, comprising administering to a subject in need thereof 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof.
A method for treating a tumor in a cancer patient given an immune checkpoint molecule regulator, comprising administering to a subject in need thereof 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof.
A method for treating a tumor in a cancer patient given 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof, comprising administering to a subject in need thereof an immune checkpoint molecule regulator.
A method for treating a tumor, comprising administering to a subject in need thereof a combination of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof and an immune checkpoint molecule regulator.
A pharmaceutical composition for preventing and/or treating a tumor, comprising 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile or a salt thereof and an immune checkpoint molecule regulator.
Dependencies are inferred from the claim text.